0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover414.65%IV-249.16%PremiumAug 16, 2024Expiry Date1.78Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7195Delta0.4297Gamma0.39Leverage Ratio-0.0051Theta-0.0011Rho-0.28Eff Leverage0.0007Vega
Allakos Stock Discussion
Allakos Announces Positive Results From Its Ongoing Phase 1 Trial of Ak006 in Healthy Volunteers, With Ak006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
Allakos has announced positive results from the Phase 1 trial of AK006, a Siglec-6 monoclonal antibody being developed to treat mast cell-driven diseases. The drug demonstrated high receptor occupancy on mast cells and a favorable safety profile, with no serious adverse events. Health...
SEC announcement
·
01/29 17:30
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2 ...
No comment yet